Air Pollution and Meteorological Conditions Significantly Associated With Vernal Keratoconjunctivitis Exacerbations.
Child
Young Adult
Humans
Air Pollutants
/ adverse effects
Nitrogen Dioxide
/ adverse effects
Conjunctivitis, Allergic
/ epidemiology
Air Pollution
/ adverse effects
Particulate Matter
/ adverse effects
Ozone
/ adverse effects
Sulfur Dioxide
/ analysis
Environmental Pollutants
Inflammation
Environmental Exposure
/ adverse effects
Journal
Investigative ophthalmology & visual science
ISSN: 1552-5783
Titre abrégé: Invest Ophthalmol Vis Sci
Pays: United States
ID NLM: 7703701
Informations de publication
Date de publication:
03 07 2023
03 07 2023
Historique:
medline:
31
7
2023
pubmed:
28
7
2023
entrez:
28
7
2023
Statut:
ppublish
Résumé
Vernal keratoconjunctivitis (VKC) is a severe chronic allergic inflammation of the ocular surface with episodes of acute exacerbations, that primarily affects children and young adults. Although the etiology and pathogenesis of VKC remain unclear, studies have suggested that environmental factors may be involved. This study aims to investigate the association between exposure to meteorological and environmental factors and the incidence of VKC exacerbations. This study was conducted in southern Israel, which is a semi-arid, hot, and dry climate with frequent dust storms. Patients diagnosed with VKC were recruited for the study. VKC exacerbations were identified as the need for medical intervention. Pollutants measured included nitrogen dioxide (NO2), ozone (O3), particulate matter (PM10 and PM2.5), sulfur dioxide (SO2), relative humidity (RH), temperature, and solar radiation (SR). To assess the association between VKC exacerbations and exposure to different pollutants, a case-crossover analysis was conducted. We also stratified the analysis by sex, age, ethnicity, immigration status, and social state score. Our results demonstrated that the pollutants NO2, O3, and PM10 were associated with VKC exacerbations with odds ratio (OR) = 2.17 (95% confidence interval [CI] =1.40 to 3.04), OR = 2.28 (95% CI = 1.30 to 3.39), and OR = 1.89 (95% CI = 1.06 to 2.74). Other pollutants PM2.5, temperature, and solar radiation were also independently associated with incidence of exacerbations with OR = 1.15 (95% CI = 0.87 to 1.50), OR = 1.75 (95% CI = 1.16 to 2.65), and OR = 1.37 (95% CI = 1.01 to 1.63) and had varying effects in different demographic strata. The environmental parameters, NO2, O3, PM10, PM2.5, temperature, and solar radiation were found to be significantly associated with VKC exacerbations, with NO2, O3, and PM10 showing the strongest associations. Our findings suggest that environmental factors should be considered when developing strategies to prevent and manage VKC exacerbations.
Identifiants
pubmed: 37504960
pii: 2791350
doi: 10.1167/iovs.64.10.37
pmc: PMC10382993
doi:
Substances chimiques
Air Pollutants
0
Nitrogen Dioxide
S7G510RUBH
Particulate Matter
0
Ozone
66H7ZZK23N
Sulfur Dioxide
0UZA3422Q4
Environmental Pollutants
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
37Références
Prog Retin Eye Res. 2002 May;21(3):319-39
pubmed: 12052387
Surv Ophthalmol. 2019 May - Jun;64(3):289-311
pubmed: 30550738
Ital J Pediatr. 2013 Mar 14;39:18
pubmed: 23497516
Br J Ophthalmol. 2008 Aug;92(8):1097-102
pubmed: 18356259
Sci Rep. 2019 Dec 3;9(1):18205
pubmed: 31796815
Acta Ophthalmol. 2009 Mar;87(2):133-47
pubmed: 18786127
Ocul Surf. 2021 Jan;19:282-289
pubmed: 33148465
Mult Scler Relat Disord. 2021 Aug;53:103043
pubmed: 34126372
Br J Ophthalmol. 2003 Jul;87(7):809-11
pubmed: 12812873
Chemosphere. 2015 Nov;139:340-8
pubmed: 26171819
Eur J Ophthalmol. 2021 Nov;31(6):2828-2842
pubmed: 34058899
J Biol Regul Homeost Agents. 2018 Jan-Feb;32(1 Suppl. 1):49-60
pubmed: 29552874
Ophthalmic Epidemiol. 2000 Jun;7(2):149-57
pubmed: 10934465
Am J Optom Physiol Opt. 1988 Aug;65(8):627-31
pubmed: 3177587
BMC Ophthalmol. 2016 Sep 29;16(1):167
pubmed: 27681885
Ann Occup Environ Med. 2018 Jun 11;30:41
pubmed: 29942521
Ophthalmology. 2000 Jun;107(6):1157-63
pubmed: 10857837
Invest Ophthalmol Vis Sci. 2012 Jan 25;53(1):429-33
pubmed: 22205603